Background
==========

Since pancreas transplantation (PT) was introduced in 1966, it has been regarded as a definitive treatment for diabetes mellitus (DM) and has been performed worldwide \[[@b1-anntransplant-23-89]--[@b3-anntransplant-23-89]\]. Various surgical techniques for graft implantation have been reported, and one of the most controversial issues has been the management of exocrine pancreatic secretions \[[@b1-anntransplant-23-89]\]. According to the International Pancreas Transplant Registry, bladder drainage is a commonly used method for exocrine drainage \[[@b2-anntransplant-23-89],[@b3-anntransplant-23-89]\]. It has several advantages \[[@b2-anntransplant-23-89]--[@b4-anntransplant-23-89]\], such as safety and enabling monitoring of urine amylase level to detect graft rejection \[[@b4-anntransplant-23-89],[@b5-anntransplant-23-89]\]. However, bladder drainage (BD) can be associated with reflux pancreatitis, metabolic acidosis, and urologic complications such as recurrent urinary tract infection, hematuria, and urethritis \[[@b4-anntransplant-23-89]--[@b6-anntransplant-23-89]\]. Because of these drawbacks, physiologic enteric drainage has been performed in 90% of cases in the United States from 2010 to 2014 \[[@b2-anntransplant-23-89]\]. However, whether enteric or bladder drainage results in better graft survival remains unclear and the optimal method for managing pancreatic exocrine secretions remains controversial.

At our institution, BD has been performed for recipients who undergo pancreas transplant alone (PTA), pancreas after kidney transplant (PAK), and simultaneous cadaveric pancreas and living donor kidney transplant (SPLK). According to the severity of complications that lead to readmission caused by recurrent urological and metabolic complications, enteric conversion (EC) may be performed. We monitor and prevent graft rejection through delayed EC after PT using bladder drainage.

We have experienced some cases of pancreas graft rejection or failure after EC within a short period. Therefore, we investigated pancreas graft rejection and survival of recipients with bladder drainage who underwent EC compared with those who did not.

Material and Methods
====================

Study population
----------------

From January 1999 to October 2015, we performed 318 PTs at our institution. Of these cases, 138 underwent enteric drainage, while 180 underwent BD. We enrolled the 180 recipients who underwent PT with bladder drainage (BD) in the present study. Of these, 97 received PTA, 10 received simultaneous pancreas--kidney transplant (SPK) from a deceased donor, 35 received SPLK, and 38 received PAK. The recipients with bladder drainage were divided into 2 groups according to whether they underwent EC or not: the EC group (n=82) and the maintain BD group (n=98) ([Figure 1](#f1-anntransplant-23-89){ref-type="fig"}).

The study was approved by our Institutional Review Board (S2015-1965-0002). The need for informed consent was waived because this was a retrospective study. The study was conducted in accordance with the 2008 Declaration of Helsinki.

Surgical procedure
------------------

The pancreas graft was placed on the right side of the pelvis with an arterial anastomosis to the iliac artery and venous anastomosis to the iliac vein. The pancreas graft duodenum was then anastomosed to the urinary bladder using two-layer side-to-side hand-sewn sutures. We selectively performed EC in recipients who had recurrent urological and metabolic complications such as urinary tract infection, hematuria, reflux graft pancreatitis, and metabolic acidosis. During EC, the duodenocystostomy was isolated and divided. Subsequently, the cystostomy was closed in 2 layers, and side-to-side duodenoenterostomy was created between the graft duodenum and jejunum, followed by distal side-to-side jejunojejunostomy using a hand-sewn two-layer approach. Roux-en-Y reconstruction was performed in recipients with significant intestinal adhesions or a shortened and thickened mesentery.

Data analysis
-------------

The clinical characteristics of the patients, such as the demographics, duration and history of DM, amount of insulin, and complications of DM, were analyzed. The following data were collected for each patient with regard to the date of EC: indication of EC, time interval between PT and EC, presence of graft rejection before and after EC, and incidence of graft loss. Rejection was diagnosed clinically or by biopsy. Delayed graft function was defined as total cumulative insulin requirement of 19UI or greater within postoperative 7 days based on our previous report \[[@b7-anntransplant-23-89]\]. Graft loss was defined as removal of the graft or re-initiation of exogenous insulin therapy. We compared the difference in graft survival between the EC and control groups and analyzed the risk factors for graft failure after EC.

Statistical analysis
--------------------

The categorical variables were analyzed with absolute and relative frequencies using the χ^2^ test. Quantitative variables were analyzed using mean and standard deviations, and differences between the means were analyzed using Student's *t* test. Graft survival was calculated using the Kaplan--Meier estimator and log-rank tests, and risk factors for graft failure were analyzed using the Cox proportional hazards regression model. Statistical calculations were performed using SPSS version 21.0 statistical software (SPSS, Chicago, IL), and p\<0.05 was considered statistically significant.

Results
=======

Characteristics and pancreas graft survival of recipients with bladder drainage
-------------------------------------------------------------------------------

Among 180 recipients who underwent PT with bladder drainage, 82 (45.6%) underwent EC. [Table 1](#t1-anntransplant-23-89){ref-type="table"} shows the demographic and clinical characteristics of recipients with or without enteric drainage. The age of DM onset was younger and there were more female recipients in the EC group. The patients in the EC group had significantly more DM retinopathy. The others were not significantly different.

During the follow-up period, reflux pancreatitis (p=0.024), metabolic acidosis (p=0.000), hematuria (p=0.001), and urinary tract infection (p=0.003) were significantly more frequent in the EC group ([Table 2](#t2-anntransplant-23-89){ref-type="table"}). Failure of the native kidney in PTA recipients or failure of the graft kidney and pancreas in SPK, PAK, and SPLK recipients was more frequent in the EC group, but the differences were not significant ([Table 2](#t2-anntransplant-23-89){ref-type="table"}).

The mean interval between PT and EC was 20±24(range 2--124, median 11.5) months. Indications for EC were recurrent urinary tract infection (n=27, 32.9%), metabolic acidosis (n=27, 32.9%), reflux pancreatitis (n=16, 19.5%), hematuria (n=11, 13.4%), and leakage of pancreatic enzyme (n=1, 1.2%).

The pancreas graft survival rate was significantly higher in the EC group for 10 years after PT than in the maintain EC group. However, after 10 years, the graft survival rate became higher in the maintain EC group ([Figure 2](#f2-anntransplant-23-89){ref-type="fig"}). To evaluate the difference of pancreas graft survival according to their transplant type, we subdivided the patients into 4 groups (SPK, PAK, PTA, and SPLK). In SPK, PAK, and SPLK groups, there were no significant differences in graft survival between the enteric conversion group and the maintain EC group (p=0.251, 0.690, and 0.750, respectively). However, we found that the pancreas graft survival in the enteric conversion group was significantly higher than in the maintain EC group (p=0.002) ([Figure 3](#f3-anntransplant-23-89){ref-type="fig"}). In the PTA group, the risk of pancreas graft failure was significantly lower in the enteric conversion group (HR=0.254, 95% confidence interval 0.101--0.637, p=0.003)

We analyzed the risk factors for pancreas graft failure after bladder drainage. In univariate analysis, recurrent urinary tract infection \[hazard ratio (HR)=0.762, p=0.025\], renal failure (HR=2.078, p=0.022), and a history of previous pancreas graft rejection (HR=3.558, p=0.000) increased the risk of graft failure, whereas EC (HR=0.395, p=0.005) lowered the risk. However, in multivariate analysis, EC (HR=0.309, p=0.000) and a history of previous pancreas graft rejection (HR=17.499, p=0.026) showed clinical significance.

Pancreas graft failure after EC
-------------------------------

After EC, 14 recipients (17.1%) experienced pancreas graft function loss. The interval between EC and graft failure was 43± 26 (range 0--93, median 42.5) months. We compared the clinical characteristics of recipients according to the incidence of graft failure. There were no significant differences in demographics ([Table 3](#t3-anntransplant-23-89){ref-type="table"}). Before EC, metabolic acidosis and immediate postoperative bleeding that required re-exploration or drainage were more common in the pancreas graft failure group ([Table 2](#t2-anntransplant-23-89){ref-type="table"}). The overall rate of renal function failure was significantly higher in the graft failure group, and native kidney failure was more common in the graft failure group ([Table 4](#t4-anntransplant-23-89){ref-type="table"}). With regard to pancreas graft function, delayed graft function and graft rejection of the pancreas before and after EC were higher in the pancreas graft failure group than in the maintain EC group ([Table 4](#t4-anntransplant-23-89){ref-type="table"}).

In univariate analysis, re-transplantation (HR=7.948, p=0.002), immediate postoperative thromboembolectomy (HR=13.096, p=0.029), metabolic acidosis (HR=4.396, p=0.023), renal failure (HR=3.143, p=0.041), delayed graft function of pancreas (HR=9.051, p=0.000), and pancreas graft rejection after EC (HR=12.729, p=0.000) significantly increased the graft failure rate. In multivariate analysis, immediate postoperative thromboembolectomy (HR=10.924, p=0.015), renal failure (HR=5.710, p=0.005), pancreas graft rejection after EC (HR=19.006, p=0.000), and delayed graft function (HR=7.021, p=0.001) had a significant relationship with graft failure ([Table 5](#t5-anntransplant-23-89){ref-type="table"}).

Discussion
==========

Enteric drainage is obviously more beneficial physiologically for managing exocrine secretions after a pancreas graft \[[@b1-anntransplant-23-89]--[@b4-anntransplant-23-89]\]. However, bladder drainage remains an important alternative because of its significant advantages in monitoring urinary amylase as a rejection marker for the pancreas \[[@b4-anntransplant-23-89]\]. The rejection of pancreas grafts occurs frequently and is often irreversible when hyperglycemia occurs; hence, bladder drainage is preferred over enteric drainage, particularly with solitary PTs. However, bladder drainage leads to several urologic and metabolic complications, such as urinary tract infection, which can affect graft survival \[[@b4-anntransplant-23-89]\]. Graft survival of the pancreas according to the type of exocrine drainage employed remains a controversial issue \[[@b8-anntransplant-23-89]--[@b11-anntransplant-23-89]\]. Grussner and Sutherland \[[@b9-anntransplant-23-89]\] showed that graft survival after 1 year was slightly lower in the group that received EC than in the group that received bladder drainage (72% *vs.* 79%) but this difference was not significant. However, the 1-year graft rejection rate was significantly higher in the group that received EC than in the group that received bladder drainage (14.6% *vs.* 5.4%). These results demonstrate that low urine amylase can be detected with bladder drainage, and treatment can be initiated at an earlier stage. Cory et al. \[[@b10-anntransplant-23-89]\] reported that recipients who underwent enteric drainage had a lower graft survival rate than those who underwent bladder drainage (77% *vs.* 88% at 6 months; 69% *vs.* 77% at 1 year), but this difference was not significant at follow-up. However, some studies showed excellent long-term outcomes for bladder drainage in addition to a lower incidence of thrombosis, early technical complications, and graft loss due to monitoring for early graft rejection and subsequent treatment \[[@b12-anntransplant-23-89]\]. At our center, the group that received enteric drainage showed significantly higher graft survival than the one that received bladder drainage ([Figure 4A](#f4-anntransplant-23-89){ref-type="fig"}). Therefore, we subdivided the bladder drainage group into an EC group and a control group and compared the graft survival in all 3 groups ([Figure 4B](#f4-anntransplant-23-89){ref-type="fig"}). In the EC group, there was no significant difference in graft survival between the individuals who underwent enteric drainage and those who underwent bladder drainage. However, the risk of graft failure was significantly higher in the latter group (HR=3.369, p=0.000). When we compared the effect of graft failure risk of EC according to their transplant type, EC significantly lowered pancreas graft failure risk in PTA recipients (HR=0.254, p=0.003). Based on these results, we confirm that EC significantly reduced the risk of pancreas graft failure, especially in PTA.

The reported conversion rate from bladder drainage to enteric drainage ranges from 10% to 40% \[[@b4-anntransplant-23-89]--[@b6-anntransplant-23-89]\]. At our center, 45.6% of recipients received EC approximately 20 months after PT and 15.9% (n=13) experienced graft rejection before EC within 253.73±33.94 (13--1125, median 101) days. After EC, there were no surgical complications such as leakage, bleeding, and re-exploration, but postoperative ileus developed in 9 recipients, recovering with conservative treatment. Many studies have reported that EC following PT does not lead to severe complications \[[@b3-anntransplant-23-89],[@b5-anntransplant-23-89],[@b6-anntransplant-23-89],[@b11-anntransplant-23-89]\]. Our data also show that graft rejection treated adequately before EC did not increase the risk of graft failure in univariate and multivariate analyses ([Table 5](#t5-anntransplant-23-89){ref-type="table"}). A history of immediate postoperative thromboembolectomy, delayed graft function, renal failure, and pancreas graft rejection after EC were risk factors for pancreas graft failure after EC ([Table 5](#t5-anntransplant-23-89){ref-type="table"}).

Some centers perform bladder drainage as a primary procedure, particularly following solitary PT, with EC performed after several months \[[@b4-anntransplant-23-89],[@b6-anntransplant-23-89],[@b11-anntransplant-23-89]\]. This two-step approach is considered to improve graft outcomes because graft rejection is monitored using urine amylase in the early stages and enteric drainage-related problems can be avoided \[[@b6-anntransplant-23-89],[@b11-anntransplant-23-89]\]. Long-term graft survival using this two-step approach is comparable to that in primary enteric drainage recipients. However, the approach can lead to unnecessary surgery and increases the cost and surgical complications in some recipients \[[@b11-anntransplant-23-89]\]. At our institution, the annual number of PTs (≥30 cases since 2012) has been steadily increasing, and approximately half are cases of PTA, with bladder drainage used to monitor the urine amylase level. Therefore, we tried to improve graft survival by monitoring urine amylase in early periods and perform the enteric conversion after about 9--12 months after PT if the recipient experienced the complications recurrently. This procedure has been maintained continuously at our center. In this study, our results show the benefit of enteric conversion after bladder drainage.

Our study has some limitations. It was a retrospective and single-center study with relatively few cases. However, our institute prefers bladder drainage after solitary PTs such as PTA, PAK, and SPLK. Therefore, we aimed to analyze which patients are best suited for EC.

Conclusions
===========

Our data show that EC approximately 9 months after PT with bladder drainage is a safe and effective method for improving short- and long-term graft survival, especially in PTA. However, the use of EC is accompanied by loss of the monitoring marker for graft rejection. Therefore, before deciding on EC, caution should be exercised for recipients with a history of immediate postoperative thromboembolectomy, delayed graft function, and renal failure. After EC, close monitoring for graft function is necessary for recipients with suspected graft rejection.

**Source of support:** None
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###### 

Clinical characteristics of recipients with bladder drainage.

                             All (n=180)   Enteric conversion (n=82)   Maintain EC (n=98)   p-Value
  -------------------------- ------------- --------------------------- -------------------- ---------
  Age of recipient (years)   34.6±11.5     33.5±10.4                   35.6±12.3            0.200
  Sex of Recipient (male)    84 (46.7%)    31 (37.8%)                  53 (54.1%)           0.029
  Type of diabetes                                                                          0.062
   Type 1                    145 (80.6%)   71 (86.6%)                  74 (75.5%)           
   Type 2                    35 (19.4%)    11 (13.4%)                  24 (24.5%)           
  Age of DM onset (years)    21.3±10.1     18.9±7.9                    23.3±11.3            0.002
  Duration of DM (years)     13.1±7.6      14.0±7.9                    12.3±7.3             0.142
  Insulin use (unit/day)     41.5±20.0     41.8±21.2                   41.2±19.0            0.824
  Complication                                                                              
   Nephropathy               83 (46.1%)    40 (48.8%)                  43 (43.9%)           0.511
   Neuropathy                28 (15.6%)    16 (19.5%)                  12 (12.2%)           0.180
   Retinopathy               111 (61.7%)   58 (70.7%)                  53 (54.1%)           0.022
  Age of donor (years)       25.9±9.2      26.8±8.5                    25.1±9.8             0.237
  Sex of donor (male)        133 (64.2%)   51 (62.2%)                  64 (66.0%)           0.599
  Follow-up (months)         49.5±45.0     61.8±45.1                   37.2±42.5            0.001
  Re-transplantation         3 (1.7%)      1 (1.2%)                    2 (2.0%)             0.668
  Induction                                                                                 0.905
   Thymoglobulin             149 (82.8%)   67 (81.7%)                  82 (83.7%)           
   Simulet                   22 (12.2%)    11 (13.4%)                  11 (11.2%)           
   Zenapax                   9 (5.0%)      4 (4.9%)                    5 (5.1%)             
  Calcineurin inhibitor                                                                     0.117
   FK506                     175 (97.2%)   78 (95.1%)                  97 (99.0%)           
   Cyclosporin               5 (2.8%)      4 (4.9%)                    1 (1.0%)             
  Antimetabolites                                                                           0.190
   MMF                       146 (81.1%)   64 (78.0%)                  82 (83.7%)           
   Myfortic                  32 (17.8%)    18 (22.0%)                  14 (14.3%)           
  Corticosteroid                                                                            0.509
   Withdrawal                138 (76.7%)   61 (74.4%)                  77 (78.6%)           
   Maintenance               42 (23.3%)    21 (25.6%)                  21 (21.4%)           

###### 

Post-transplant complications in recipients.

                                             Bladder drainage (n=180)   Enteric conversion (n=82)                                     
  ------------------------------------------ -------------------------- --------------------------- ------- ------------ ------------ -------
  Postoperative bleeding                     7 (8.5%)                   18 (18.4%)                  0.058   4 (5.9%)     3 (21.4%)    0.058
  Thrombosis                                 23 (28.0%)                 36 (36.%7)                  0.213   21 (30.9%)   2 (14.3%)    0.208
  Thromboembolectomy                         3 (3.7%)                   6 (6.1%)                    0.450   2 (2.9%)     1 (7.1%)     0.446
  Leakage                                    5 (6.1%)                   1 (1.0%)                    0.059   4 (5.9%)     1 (7.1%)     0.858
  Reflux pancreatitis                        31 (37.8%)                 22 (22.4%)                  0.024   23 (33.8%)   8 (57.1%)    0.101
  Metabolic acidosis                         39 (47.6%)                 18 (18.4%)                  0.000   28 (42.1%)   11 (78.6%)   0.011
  Hematuria                                  25 (30.5%)                 10 (10.2%)                  0.001   19 (27.6%)   6 (42.9%)    0.270
  Urinary tract infection                    59 (72.0%)                 49 (50.0%)                  0.003   50 (73.5%)   9 (64.3%)    0.483
  Kidney failure                             11 (13.4%)                 5 (5.1%)                    0.051                             
  Past history of pancreas graft rejection   21 (25.6%)                 16 (16.3%)                  0.125                             
  Pancreas graft failure                     14 (17.1%)                 28 (28.6%)                  0.069                             

###### 

Clinical characteristics of recipients with enteric conversion according to the presence of graft failure.

                                                                      No graft failure (n=68)   Graft failure (n=14)   p-Value
  ------------------------------------------------------------------- ------------------------- ---------------------- ---------
  Age of recipient (years)                                            33.4±10.3                 33.7±11.2              0.933
  Sex of Recipient (male)                                             25 (36.8%)                6 (42.6%)              0.669
  Type of diabetes                                                                                                     0.068
   Type 1                                                             61 (89.7%)                10 (71.4%)             
   Type 2                                                             7 (10.3%)                 4 (28.6%)              
  Age of DM onset (years)                                             19.3±7.7                  17.2±8.8               0.370
  Duration of DM (years)                                              13.5±8.3                  16.4±5.3               0.214
  Insulin use (unit/day)                                              42.9±22.4                 36.9±13.5              0.352
  Complication                                                                                                         
   Nephropathy                                                        32 (47.1%)                8 (57.1%)              0.492
   Neuropathy                                                         14 (20.6%)                2 (14.3%)              0.588
   Retinopathy                                                        48 (70.6%)                10 (71.4%)             0.950
  Age of donor (years)                                                26.1±8.3                  30.4±9.4               0.089
  Sex of donor (male)                                                 42 (61.8%)                9 (64.3%)              0.859
  Follow-up (months)                                                  50.9±34.7                 43.0±26.9              0.425
  Re-transplantation                                                  0                         1 (7.1%)               0.027
  PRA Class I                                                         7.7±19.3                  5.9±19.7               0.257
   (MFI)                                                              116.5±467.0               0                      0.752
  PRA Class II                                                        3.8±9.3                   7.7±2.3                0.633
   (MFI)                                                              87.8±42.3                 0                      0.562
  Cold ischemic time (min)                                            357.4±139.2               375.8±149.6            0.658
  Induction                                                                                                            0.158
   Thymoglobulin                                                      58 (85.3%)                9 (64.3%)              
   Simulet                                                            7 (10.3%)                 4 (28.6%)              
   Zenapax                                                            3 (4.4%)                  1 (7.1%)               
  Calcineurin inhibitor                                                                                                0.666
   FK506                                                              65 (95.6%)                13 (92.9%)             
   Cyclosporin                                                        3 (4.4%)                  1 (7.1%)               
  Antimetabolites                                                                                                      0.142
   MMF                                                                51 (75.0%)                13 (92.9%)             
   Myfortic                                                           17 (25.0%)                1 (7.1%)               
  Corticosteroid                                                                                                       0.780
   Withdrawal                                                         51 (75.0%)                10 (71.4%)             
   Maintenance                                                        17 (25.0%)                4 (28.6%)              
  Time from pancreas transplantation to enteric conversion (months)   19.1±23.5                 26.6±28.1              0.299
  Cause of enteric conversion                                                                                          0.336
   Urinary tract infection                                            23 (33.8%)                4 (28.6%)              
   Metabolic acidosis                                                 22 (32.4%)                5 (35.7%)              
   Reflux pancreatitis                                                15 (22.1%)                1 (7.1%)               
   Hematuria                                                          7 (10.3%)                 4 (28.6%)              
   Leakage                                                            1 (1.5%)                  0                      

###### 

The effect of renal function and pancreas graft function on graft failure after enteric conversion.

                                                                                           No graft failure (n=68)   Graft failure (n=14)   p-Value
  ---------------------------------------------------------------------------------------- ------------------------- ---------------------- ---------
  Kidney failure                                                                           7 (10.3%)                 5 (35.7%)              0.014
   Native kidney                                                                           5 (14.3%)                 3 (50.0%)              0.041
   Graft kidney                                                                            2 (6.1%)                  2 (25.0%)              0.105
  Graft kidney rejection                                                                                                                    
   Before enteric conversion                                                               7/33 (21.2%)              2/8 (25.0%)            0.816
   After enteric conversion                                                                2/33 (6.1%)               0                      0.475
  Delayed graft function of pancreas[\*](#tfn1-anntransplant-23-89){ref-type="table-fn"}   0                         5 (35.7%)              0.000
  Pancreas graft rejection                                                                                                                  
   Before enteric conversion                                                               11 (16.2%)                3 (21.4%)              0.002
   Interval from PT to rejection (days)                                                    102.3±109.2               470.5±586.2            0.075
   After enteric conversion                                                                1 (1.5%)                  7 (50%)                0.000
   Interval from enteric conversion to rejection (days)                                    423.5±586.2               764.0±499.5            0.415

Delayed graft function of pancreas was defined as a total cumulative insulin requirement of 19 UI or greater within postoperative 7 days.

###### 

Risk factor of pancreas graft failure after enteric conversion.

                                                       Univariate               Multivariate                            
  ---------------------------------------------------- ------------------------ -------------- ------------------------ -------
  Postoperative bleeding                               3.296 (0.913--11.904)    0.069                                   
  Postoperative thromboembolectomy                     13.096 (1.300--23.190)   0.029          10.924 (1.788--24.862)   0.015
  Reflux pancreatitis                                  2.524 (0.873--7.294)     0.087                                   
  Metabolic acidosis                                   4.396 (1.225--15.785)    0.023          3.109 (0.816--11.846)    0.096
  Re-transplantation                                   7.948 (1.497--12.709)    0.002                                   
  Delayed graft function                               9.051 (2.947--17.797)    0.000          7.021 (2.012--23.195)    0.001
  Pancreas graft rejection before enteric conversion   1.008 (0.202--5.021)     0.092                                   
  Pancreas graft rejection after enteric conversion    12.729 (4.260--28.031)   0.000          19.006 (5.718--23.168)   0.000
  Renal failure                                        3.143 (1.050--9.410)     0.041          5.710 (1.700--19.181)    0.005
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